{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:04:12Z","timestamp":1791144252881,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1124\/jpet.105.084673","type":"journal-article","created":{"date-parts":[[2005,6,17]],"date-time":"2005-06-17T02:07:56Z","timestamp":1118974076000},"page":"232-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Inhibition of Platelet Functions and Thrombosis through Selective or Nonselective Inhibition of the Platelet P2 Receptors with Increasing Doses of NF449 [4,4\u2032,4\u2033,4\u2033\u2032-(Carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic Acid Octasodium Salt]"],"prefix":"10.1016","volume":"314","author":[{"given":"B\u00e9atrice","family":"Hechler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Magnenat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena L.","family":"Zighetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias U.","family":"Kassack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Ullmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Cazenave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.105.084673_bib1","doi-asserted-by":"crossref","unstructured":"Baurand A, Eckly A, Bari N, L\u00e9on C, Hechler B, Cazenave JP, and Gachet C (2000) Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost 84: 484-491.","DOI":"10.1055\/s-0037-1614049"},{"key":"10.1124\/jpet.105.084673_bib2","doi-asserted-by":"crossref","unstructured":"Baurand A and Gachet C (2003) The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179. Cardiovasc Drug Rev 21: 67-76.","DOI":"10.1111\/j.1527-3466.2003.tb00106.x"},{"key":"10.1124\/jpet.105.084673_bib3","doi-asserted-by":"crossref","unstructured":"Baurand A, Raboisson P, Freund M, L\u00e9on C, Cazenave JP, Bourguignon JJ, and Gachet C (2001) Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol 412: 213-221.","DOI":"10.1016\/S0014-2999(01)00733-6"},{"key":"10.1124\/jpet.105.084673_bib4","doi-asserted-by":"crossref","unstructured":"Braun K, Rettinger J, Ganso M, Kassack M, Hildebrandt C, Ullmann H, Nickel P, Schmalzing G, and Lambrecht G (2001) NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 364: 285-290.","DOI":"10.1007\/s002100100463"},{"key":"10.1124\/jpet.105.084673_bib5","doi-asserted-by":"crossref","unstructured":"CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329-1339.","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"10.1124\/jpet.105.084673_bib6","doi-asserted-by":"crossref","unstructured":"Cattaneo M, Lombardi R, Bettega D, Lecchi A, and Mannucci PM (1993) Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb 13: 393-397.","DOI":"10.1161\/01.ATV.13.3.393"},{"key":"10.1124\/jpet.105.084673_bib7","unstructured":"Cattaneo M, Marchese P, Jacobson KA, and Ruggeri Z (2002) New insights into the role of P2X1 in platelet function. Haematologica 87: 13-14."},{"key":"10.1124\/jpet.105.084673_bib8","doi-asserted-by":"crossref","unstructured":"Cazenave JP and Gachet C (2002) Pharmacology of ticlopidine and clopidogrel, in Platelets in Thrombotic and Non-Thrombotic Disorders (Gresele P, Page C, Fuster V and Vermylen J eds) pp 929-939, Cambridge University Press, Cambridge, UK.","DOI":"10.1017\/CBO9780511545283.063"},{"key":"10.1124\/jpet.105.084673_bib9","doi-asserted-by":"crossref","unstructured":"Cazenave JP, Ohlmann P, Cassel D, Eckly A, Hechler B, and Gachet C (2004) Preparation of washed platelet suspensions from human and rodent blood. Methods Mol Biol 272: 13-28.","DOI":"10.1385\/1-59259-782-3:013"},{"key":"10.1124\/jpet.105.084673_bib10","doi-asserted-by":"crossref","unstructured":"Conley PB and Delaney SM (2003) Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. Curr Opin Hematol 10: 333-338.","DOI":"10.1097\/00062752-200309000-00002"},{"key":"10.1124\/jpet.105.084673_bib11","doi-asserted-by":"crossref","unstructured":"DiMinno G and Silver MJ (1983) Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther 225: 57-60.","DOI":"10.1016\/S0022-3565(25)33551-2"},{"key":"10.1124\/jpet.105.084673_bib12","doi-asserted-by":"crossref","unstructured":"Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, and Koller BH (1999) Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 5: 1199-1202.","DOI":"10.1038\/13522"},{"key":"10.1124\/jpet.105.084673_bib13","doi-asserted-by":"crossref","unstructured":"Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ Jr, Wiekowski MT, et al. (2001) Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Investig 107: 1591-1598.","DOI":"10.1172\/JCI12242"},{"key":"10.1124\/jpet.105.084673_bib14","doi-asserted-by":"crossref","unstructured":"Gachet C (2001) ADP receptors of platelets and their inhibition. Thromb Haemost 86: 222-232.","DOI":"10.1055\/s-0037-1616220"},{"key":"10.1124\/jpet.105.084673_bib15","doi-asserted-by":"crossref","unstructured":"Gachet C and Hechler B (2005) The platelet P2 receptors in thrombosis. Semin Thromb Haemost 31: 62-67.","DOI":"10.1055\/s-2005-869521"},{"key":"10.1124\/jpet.105.084673_bib16","doi-asserted-by":"crossref","unstructured":"Hechler B, Cattaneo M, and Gachet C (2005) The P2 receptors in platelet function. Semin Thromb Haemost 31: 150-161.","DOI":"10.1055\/s-2005-869520"},{"key":"10.1124\/jpet.105.084673_bib17","doi-asserted-by":"crossref","unstructured":"Hechler B, Lenain N, Marchese P, Vial C, Heim V, Freund M, Cazenave JP, Cattaneo M, Ruggeri ZM, Evans R, et al. (2003) A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med 198: 661-667.","DOI":"10.1084\/jem.20030144"},{"key":"10.1124\/jpet.105.084673_bib18","doi-asserted-by":"crossref","unstructured":"Hulsmann M, Nickel P, Kassack M, Schmalzing G, Lambrecht G, and Markwardt F (2003) NF449, a novel picomolar potency antagonist at human P2X1 receptors. Eur J Pharmacol 470: 1-7.","DOI":"10.1016\/S0014-2999(03)01761-8"},{"key":"10.1124\/jpet.105.084673_bib19","doi-asserted-by":"crossref","unstructured":"Jin J, Daniel JL, and Kunapuli SP (1998) Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 273: 2030-2034.","DOI":"10.1074\/jbc.273.4.2030"},{"key":"10.1124\/jpet.105.084673_bib20","doi-asserted-by":"crossref","unstructured":"Kassack M and Nickel P (1996) Rapid, highly sensitive gradient narrow-bore high-performance liquid chromatographic determination of suramin and its analogues. J Chromatogr B Biomed Appl 686: 275-284.","DOI":"10.1016\/S0378-4347(96)00214-9"},{"key":"10.1124\/jpet.105.084673_bib21","doi-asserted-by":"crossref","unstructured":"Kassack MU, Braun K, Ganso M, Ullmann H, Nickel P, Boing B, Muller G, and Lambrecht G (2004) Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem 39: 345-357.","DOI":"10.1016\/j.ejmech.2004.01.007"},{"key":"10.1124\/jpet.105.084673_bib22","doi-asserted-by":"crossref","unstructured":"Kauffenstein G, Bergmeier W, Eckly A, Ohlmann P, L\u00e9on C, Cazenave JP, Nieswandt B, and Gachet C (2001) The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin\u2014a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett 505: 281-290.","DOI":"10.1016\/S0014-5793(01)02824-1"},{"key":"10.1124\/jpet.105.084673_bib23","doi-asserted-by":"crossref","unstructured":"Lambrecht G (2000) Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 362: 340-350.","DOI":"10.1007\/s002100000312"},{"key":"10.1124\/jpet.105.084673_bib24","doi-asserted-by":"crossref","unstructured":"Lambrecht G, Braun K, Damer M, Ganso M, Hildebrandt C, Ullmann H, Kassack MU, and Nickel P (2002) Structure-activity relationships of suramin and pyridoxal-5\u2032-phosphate derivatives as P2 receptor antagonists. Curr Pharm Des 8: 2371-2399.","DOI":"10.2174\/1381612023392973"},{"key":"10.1124\/jpet.105.084673_bib25","unstructured":"Lenain N, Freund M, Hechler B, L\u00e9on C, Evans R, Cazenave JP, and Gachet C (2003a) The role of the P2Y1, P2Y12 and P2X1 platelet receptors in a laser induced model of arterial thrombosis in vivo (Abstract). J Thromb Haemost; 2003 July 13-18; Burmingham, UK."},{"key":"10.1124\/jpet.105.084673_bib26","doi-asserted-by":"crossref","unstructured":"Lenain N, Freund M, L\u00e9on C, Cazenave JP, and Gachet C (2003b) Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Haemost 1: 1144-1149.","DOI":"10.1046\/j.1538-7836.2003.00144.x"},{"key":"10.1124\/jpet.105.084673_bib27","doi-asserted-by":"crossref","unstructured":"L\u00e9on C, Freund M, Ravanat C, Baurand A, Cazenave JP, and Gachet C (2001) Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation 103: 718-723.","DOI":"10.1161\/01.CIR.103.5.718"},{"key":"10.1124\/jpet.105.084673_bib28","doi-asserted-by":"crossref","unstructured":"L\u00e9on C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, and Gachet C (1999) Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Investig 104: 1731-1737.","DOI":"10.1172\/JCI8399"},{"key":"10.1124\/jpet.105.084673_bib29","doi-asserted-by":"crossref","unstructured":"Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, Cobb AL, Brown JE, Conley EC, Buell G, Pritchard CA, et al. (2000) Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature (Lond) 403: 86-89.","DOI":"10.1038\/47495"},{"key":"10.1124\/jpet.105.084673_bib30","doi-asserted-by":"crossref","unstructured":"Ohlmann P, Eckly A, Freund M, Cazenave JP, Offermanns S, and Gachet C (2000) ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood 96: 2134-2139.","DOI":"10.1182\/blood.V96.6.2134"},{"key":"10.1124\/jpet.105.084673_bib31","unstructured":"Ohlmann P, Hechler B, Cazenave JP, and Gachet C (2004) Measurement and manipulation of [Ca2+]i in suspensions of platelets and cell cultures. Methods Mol Biol 273: 229-250."},{"key":"10.1124\/jpet.105.084673_bib32","doi-asserted-by":"crossref","unstructured":"Oury C, Kuijpers MJ, Toth-Zsamboki E, Bonnefoy A, Danloy S, Vreys I, Feijge MA, De Vos R, Vermylen J, Heemskerk JW, et al. (2003) Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood 101: 3969-3976.","DOI":"10.1182\/blood-2002-10-3215"},{"key":"10.1124\/jpet.105.084673_bib33","doi-asserted-by":"crossref","unstructured":"Oury C, Sticker E, Cornelissen H, De Vos R, Vermylen J, and Hoylaerts MF (2004) ATP augments von Willebrand factor-dependent shear-induced platelet aggregation through Ca2+-calmodulin and myosin light chain kinase activation. J Biol Chem 279: 26266-26273.","DOI":"10.1074\/jbc.M402032200"},{"key":"10.1124\/jpet.105.084673_bib34","doi-asserted-by":"crossref","unstructured":"Oury C, Toth-Zsamboki E, Thys C, Tytgat J, Vermylen J, and Hoylaerts MF (2001) The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb Haemost 86: 1264-1271.","DOI":"10.1055\/s-0037-1616060"},{"key":"10.1124\/jpet.105.084673_bib35","unstructured":"Peters G and Robbie G (2004) Single dose pharmacokinetics and pharmacodynamics of AZD6140-an oral reversible ADP receptor antagonist. Haematologica 89: 14-15."},{"key":"10.1124\/jpet.105.084673_bib36","doi-asserted-by":"crossref","unstructured":"Rolf MG, Brearley CA, and Mahaut-Smith MP (2001) Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. Thromb Haemost 85: 303-308.","DOI":"10.1055\/s-0037-1615684"},{"key":"10.1124\/jpet.105.084673_bib37","doi-asserted-by":"crossref","unstructured":"Savi P and Herbert JM (2005) Clopidogrel and ticlopidine: P2Y12 ADP-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Haemost, in press.","DOI":"10.1055\/s-2005-869523"},{"key":"10.1124\/jpet.105.084673_bib38","doi-asserted-by":"crossref","unstructured":"Savi P, Labouret C, Delesque N, Guette F, Lupker J, and Herbert JM (2001) P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 283: 379-383.","DOI":"10.1006\/bbrc.2001.4816"},{"key":"10.1124\/jpet.105.084673_bib39","doi-asserted-by":"crossref","unstructured":"Takano S, Kimura J, Matsuoka I, and Ono T (1999) No requirement of P2X1 purinoceptors for platelet aggregation. Eur J Pharmacol 372: 305-309.","DOI":"10.1016\/S0014-2999(99)00201-0"},{"key":"10.1124\/jpet.105.084673_bib40","doi-asserted-by":"crossref","unstructured":"Vial C, Hechler B, L\u00e9on C, Cazenave JP, and Gachet C (1997) Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost 78: 1500-1504.","DOI":"10.1055\/s-0038-1665441"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524320786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524320786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.105.084673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:29:37Z","timestamp":1740000577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524320786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0022356524320786"],"URL":"https:\/\/doi.org\/10.1124\/jpet.105.084673","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of Platelet Functions and Thrombosis through Selective or Nonselective Inhibition of the Platelet P2 Receptors with Increasing Doses of NF449 [4,4\u2032,4\u2033,4\u2033\u2032-(Carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic Acid Octasodium Salt]","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.105.084673","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2005 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}